35
Participants
Start Date
August 28, 2018
Primary Completion Date
December 22, 2021
Study Completion Date
December 22, 2021
Melflufen
Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
Dexamethasone
Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno
University Hospital Olomouc, Clinic of Hemato-Oncology, Olomouc
General University Hospital in Prague, 1st Internal Clinic - Clinic of Hematology, Prague
"General Hospital of Athens Evangelismos", Athens
General Hospital of Athens Alexandra, Therapeutic Clinic, Athens
University General Hospital of Patras, Pátrai
Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka, Torun
Maria Sklodowska-Curie Institute of Oncology, Branch in Gliwice, Department of Bone Marrow Transplantation and Hematologic Oncology, Gliwice
Independent Public Healthcare Facility Municipal Hospitals, Department of Hematology, Katowice
Independent Public Teaching Hospital No.1 in Lublin, Department of Hematooncology, Bone Marrow Transplantation and Chemotherapy, Lublin
Lead Sponsor
Oncopeptides AB
INDUSTRY